Standard BioTools Inc.
LAB Healthcare Medical Devices
In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow LAB
Standard BioTools Inc. (LAB) Altman Z-score
Standard BioTools Inc.'s Altman Z-score for fiscal 2025 is −0.82, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −0.82 | (0.82) |
| FY2024 | −0.00 | 3.95 |
| FY2023 | −3.95 | (0.75) |
| FY2022 | −3.20 | (0.21) |
| FY2021 | −2.99 | (1.61) |
| FY2020 | −1.38 | 0.58 |
| FY2019 | −1.96 | (0.47) |
| FY2018 | −1.49 | 0.55 |
| FY2017 | −2.04 | (0.35) |
| FY2016 | −1.69 | (1.28) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.61 | — | 0.73 | |
| Retained earnings / total assets | (2.22) | — | −3.11 | |
| EBIT / total assets | (0.19) | — | −0.64 | |
| Market value of equity / total liabilities | 3.40 | — | 2.04 | |
| Sales / total assets | 0.15 | — | 0.15 | |
| Altman Z-score | Distress zone | −0.82 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −1.44 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ELMD Electromed, Inc. compare | 20.3× |
| PROF Profound Medical compare | 7.3× |
| INFU InfuSystems Holdings, Inc. compare | 3.7× |
| CLPT ClearPoint Neuro, Inc. compare | 0.4× |
| QSI Quantum-Si Incorporated compare | 0.4× |
| TMCI Treace Medical Concepts, Inc. compare | −0.1× |
| CATX Perspective Therapeutics, Inc. compare | −0.6× |
| LAB Standard BioTools Inc. | −0.8× |
| TLSI TriSalus Life Sciences, Inc. compare | −11.3× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets